Zolgensma
1 known investors
ZOLGENSMA is a one-time gene replacement therapy for treating spinal muscular atrophy (SMA) in children under 2 years old, aiming to stop disease progression and support developmental milestones such as sitting, standing, and walking. It is marketed by Novartis, which also provides patient support services for families choosing the treatment.
BiotechDigital HealthHealthtech
Investors · 1
Frequently asked questions
- What does Zolgensma do?
- ZOLGENSMA is a one-time gene replacement therapy for treating spinal muscular atrophy (SMA) in children under 2 years old, aiming to stop disease progression and support developmental milestones such as sitting, standing, and walking. It is marketed by Novartis, which also provides patient support services for families choosing the treatment.
- Who are Zolgensma's investors?
- Zolgensma's investors include HEALTHCARE ROYALTY PARTNERS.